Regeneron Pharmaceuticals (REGN) 10-K2014 FY Annual report

Filed: 12 Feb 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: abicipar, accidental, acetonide, agonist, Alimera, allergy, anacetrapib, arthralgia, Atara, Australian, automatically, automation, Avalanche, Aventisub, backup, Baylor, Bispecific, Breakthrough, BSA, CETP, childbearing, CHMP, cholesterylester, classification, clearing, cloud, COMBO, concomitantly, concurrent, confidence, corticosteroid, CSwNP, CT, CV, CVD, Delaware, delineated, deliverable, description, dexamethasone, disagree, dismissing, disturbance, double, draining, drip, EASI, eczema, endoscopic, EoE, EPO, ESC, Esperion, EULAR, evacetrapib, explicit, extinguishment, fashion, FH, Fifty, float, fluocinolone, forfeiture, formulary, frame, franchise, Francisco, goodwill, Hague, hazard, hearing, herpeticum, hospitalization, hypercholesterolemic, IGA, Iluvien, image, immunosuppressant, implant, implicate, imposition, inadvertently, incremental, ingram, inhaled, intervened, intranasal, IPO, IRS, itching, Labour, League, ligament, loading, lot, LS, lymphopoietin, MAA, media, MHLW, Ministry, ml, molecular, MONARCH, municipal, musculoskeletal, myalgia, narrow, NDA, NME, nose, notified, novelty, NPS, NRS, numerically, obstruction, opthalmology, oropharyngeal, overdose, Ozurdex, pediatric, pegol, petitioned, Pfenex, pharmacy, Polyp, pool, Portability, postmarketing, postnasal, PRALUENT, PRALUENTTM, prejudice, preserve, principle, ratio, reacquisition, reassessed, reconsider, registry, reinstating, reliance, retrospectively, Rheumatism, Rheumatology, room, rosuvastatin, rosuvastatine, RSV, runny, San, scan, SCORAD, sense, served, Sick, skin, sleep, slower, smell, SOLO, sprain, spray, stromal, surgery, swallowing, syncytial, task, threshold, throughput, thymic, tissue, topline, TSLP, uncontrolled, unenforceable, University, upcoming, Utrecht, visit, voucher, Welfare, women

Removed: accrual, agree, allocation, amortizing, BDNF, bevacizumab, breakdown, canceled, chemotherapy, Chugai, closely, collateral, collateralize, collateralized, computation, concept, conclusion, considerably, Convertase, damaged, deducting, default, defer, dispute, divided, eric, essential, experimental, expressed, functional, gave, inclusion, institutional, Kabushiki, Kaisha, kinase, leaky, leasehold, light, MedImmune, modify, multinational, novation, OncoMed, Onyx, ordered, positively, prepayment, proof, Proprotein, remodeling, repair, resolved, satisfaction, Seiyaku, sensitization, shooter, Society, solid, strongly, successor, suggesting, tocilizumab, UK, unamortized, upregulated, vessel, VIEW, withheld, withholding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

REGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, and 333-198794) and on Form S‑3 (No. 333-192091) of Regeneron Pharmaceuticals, Inc., of our report dated February 12, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.

/s/ PricewaterhouseCoopers LLP

Florham Park, New Jersey

February 12, 2015